See more : Nichi-Iko Pharmaceutical Co., Ltd. (4541.T) Income Statement Analysis – Financial Results
Complete financial analysis of Intensity Therapeutics, Inc. (INTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intensity Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jiangsu Zhongli Group Co.,Ltd (002309.SZ) Income Statement Analysis – Financial Results
- Premier Graphene Inc (BIEI) Income Statement Analysis – Financial Results
- Procaps Group, S.A. (PROCW) Income Statement Analysis – Financial Results
- Hangzhou Landscaping Incorporated (605303.SS) Income Statement Analysis – Financial Results
- NACL Industries Limited (NACLIND.NS) Income Statement Analysis – Financial Results
Intensity Therapeutics, Inc. (INTS)
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 147.00K | 179.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -147.00K | -179.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.79M | 5.13M | 5.86M | 5.05M | 4.44M |
| General & Administrative | 3.53M | 2.42M | 2.16M | 1.17M | 1.24M |
| Selling & Marketing | -147.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.39M | 2.42M | 2.16M | 1.17M | 1.24M |
| Other Expenses | 0.00 | 47.65K | 115.51K | 118.76K | 144.99K |
| Operating Expenses | 8.17M | 7.55M | 8.01M | 6.22M | 5.68M |
| Cost & Expenses | 8.32M | 7.55M | 8.01M | 6.22M | 5.68M |
| Interest Income | 324.00K | 2.48K | 2.61K | 74.01K | 150.71K |
| Interest Expense | 305.00K | 81.78K | 16.77K | 0.00 | 0.00 |
| Depreciation & Amortization | 147.00K | 179.04K | 236.56K | 206.30K | 171.86K |
| EBITDA | -10.09M | -7.40M | -7.88M | -6.03M | -5.38M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.32M | -7.63M | -8.01M | -6.22M | -5.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.22M | 49.06K | 118.12K | 192.77K | 295.70K |
| Income Before Tax | -10.54M | -7.58M | -7.90M | -6.03M | -5.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -131.91K | -2.61K | -74.01K | -150.71K |
| Net Income | -10.54M | -7.45M | -7.89M | -5.96M | -5.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.38 | -0.57 | -0.60 | -0.45 | -0.40 |
| EPS Diluted | -1.38 | -0.57 | -0.60 | -0.45 | -0.40 |
| Weighted Avg Shares Out | 8.62M | 13.10M | 13.10M | 13.10M | 13.10M |
| Weighted Avg Shares Out (Dil) | 8.62M | 13.10M | 13.10M | 13.10M | 13.10M |
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
U.S. IPO Weekly Recap: Sizable Deals Close Out The Q2 IPO Market, Led By Thrift Store Savers
Source: https://incomestatements.info
Category: Stock Reports